Bionovo (BNVI) a clinical-stage drug discovery and development company, focuses on the development drug candidates in the areas of women's health and cancer. The company's drug development process utilizes botanical sources used in traditional Chinese medicine to produce biologically active compounds.
Bionovo's lead drug candidate, Menerba, which completed phase 2 clinical trail and progressing into phase 3.
Improving Women’s Health 40 million women in America are of menopausal age, an estimated 75% to 85% experience significant and unpleasant side effects due to declining and fluctuating hormone levels. These problems include vaginal dryness, depression and weight gain. Existing therapies represent a multi-billion dollar market. Bionovo is striving to provide a safe, reliable, and clinically proven therapy to fill this unmet need.
The company also develops Bezielle, an oral anti-cancer agent that completed two separate phase 1 clinical trails for the treatment of advanced breast cancer. Seala, a preclinical drug candidate for the treatment of post-menopausal vulvar and vaginal atrophy.
Conquering Cancer Breast cancer is the second leading cause of cancer deaths in the United States, and more than 200,000 new cases are diagnosed each year. As a result, breast cancer takes more than 40,000 lives annually.
The company successfully raised funds and appointed new executives and board members. The stock is trading near 52WK LOWS could bounce back, keep an eye!
Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®
we receive compensation from companies we feature. Always Read the full Disclosure/Disclaimer. Thanks.